Microfluidic In Vitro Platform for (Nano)Safety and (Nano)Drug Efficiency Screening

Area of Science:

• Biotechnology
• Toxicology
• In Vitro Models

Background:

• Growing demand for animal-free testing in drug development and chemical safety assessment (REACH).
• Microfluidic technology offers miniaturization, high-throughput screening, and reduced reagent consumption for in vitro models.
• Existing methods often lack the in vivo-like cellular and organ-level responses needed for accurate risk assessment.

Purpose of the Study:

• To develop and validate a novel microfluidic platform for in vivo-like in vitro cell cultivation.
• To demonstrate label-free assessment of cytotoxic effects using integrated electrodes and microscopy.
• To enable flexible interconnection of modules for simulating whole-body exposure and response.

Main Methods:

• Development of a microfluidic platform with a silicon chip, integrated electrodes, and a microcavity.
• Utilizing a miniaturized microscope for monitoring cell morphology and proliferation.
• Noninvasive monitoring of barrier integrity via integrated electrodes.
• Label-free assessment of cytotoxic effects on various cell models.

Main Results:

• Proof-of-concept demonstrated suitability for label-free cytotoxicity assessment across different cell models.
• Integrated electrodes enabled noninvasive monitoring of barrier integrity.
• Miniaturized microscopy allowed real-time observation of cell health and proliferation.
• Individual or interconnected module operation confirmed platform flexibility.

Conclusions:

• The developed microfluidic platform provides a powerful tool for in vivo-like in vitro cell cultivation and testing.
• It enables efficient, label-free assessment of cytotoxic effects, contributing to animal-free risk assessment.
• The platform supports the 3Rs principles (replace, reduce, refine) for animal experiments in toxicology and drug development.